MR4 Stock Overview Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Meridian Bioscience, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Meridian Bioscience Historical stock prices Current Share Price US$30.90 52 Week High US$33.18 52 Week Low US$18.52 Beta 0.23 1 Month Change 0.26% 3 Month Change -5.99% 1 Year Change 63.75% 3 Year Change 312.00% 5 Year Change 160.98% Change since IPO 1,254.40%
Recent News & Updates SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others. Feb 01
Full year 2022 earnings released: EPS: US$0.97 (vs US$1.65 in FY 2021) Nov 23
Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022 Nov 23
Insufficient new directors Nov 16
Impactive Capital Provides Information to Shareholders of Meridian Bioscience Oct 31
Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 profit in 3Q 2021) Aug 06 See more updates SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others. Feb 01
Full year 2022 earnings released: EPS: US$0.97 (vs US$1.65 in FY 2021) Nov 23
Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022 Nov 23
Insufficient new directors Nov 16
Impactive Capital Provides Information to Shareholders of Meridian Bioscience Oct 31
Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 profit in 3Q 2021) Aug 06
Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022 Aug 06
Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay Jul 30 SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion. Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays Jun 21
Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests May 27
Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays May 18
Insufficient new directors May 16
Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022 Apr 08 Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President
Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits Feb 17
Investor sentiment improved over the past week Feb 11
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 05
Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022 Feb 05
Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection Jan 30
Meridian Bioscience, Inc. Announces Board Changes Jan 28
Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay Jan 06
Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020) Nov 13
Insufficient new directors Nov 01
Insufficient new directors Oct 02
Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples Sep 08
Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020) Aug 08
Investor sentiment deteriorated over the past week Jul 16
Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021 Jul 15
Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix Jun 17
Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples May 18
Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021 May 08
Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020) May 08
Meridian Bioscience, Inc. Announces the Launch of the Lyo-Ready DNA LAMP Mix Apr 29
Investor sentiment improved over the past week Apr 02
President recently sold €210k worth of stock Mar 16
Investor sentiment improved over the past week Mar 12
Meridian Bioscience, Inc. Announces the Launch of New Air-Dryable Direct DNA qPCR Blood Mix Mar 10 Meridian Bioscience Provides A Further Update on the Revogene® Sars-Cov-2 Eua Submission
Investor sentiment deteriorated over the past week Feb 21
Meridian Bioscience, Inc. Provides an Update on the Revogene SARS-CoV-2 EUA Submission Feb 18
First quarter 2021 earnings released: EPS US$0.62 (vs US$0.066 in 1Q 2020) Feb 07
Revenue beats expectations Feb 07
Meridian Bioscience, Inc. Raises Consolidated Earnings Guidance for the Fiscal Year 2021 Feb 06
Investor sentiment improved over the past week Feb 06
Meridian’s Air-Dryable Master Mixes Replace Lyophilization in the Manufacturing of Molecular Assays Feb 03
New 90-day high: €18.70 Jan 26
Meridian Bioscience, Inc. to Report Q1, 2021 Results on Feb 05, 2021 Jan 14
Investor sentiment improved over the past week Jan 11
New 90-day high: €17.70 Jan 07
New 90-day high: €17.00 Dec 23
Meridian Bioscience, Inc., Annual General Meeting, Jan 27, 2021 Dec 17
Meridian Bioscience, Inc. Launches Its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers Dec 04
Independent Director recently bought €74k worth of stock Dec 02
Market bids up stock over the past week Nov 22
Full year 2020 earnings released: EPS US$1.08 Nov 14
Revenue beats expectations Nov 14
Market pulls back on stock over the past week Nov 11
Meridian Bioscience, Inc. Launches Complete Solution Improving the Development of Cancer Diagnostic Tests Oct 08
New 90-day low - €11.90 Aug 28
Third quarter earnings released Aug 08
New 90-day high - €22.20 Aug 06
Meridian Bioscience, Inc. (NasdaqGS:VIVO) completed the acquisition of Exalenz Bioscience Ltd (TASE:EXEN) from Mori Arkin and others. Jul 31
Meridian Bioscience, Inc. to Report Q3, 2020 Results on Aug 07, 2020 Jul 18 Shareholder Returns MR4 DE Medical Equipment DE Market 7D 0.9% -2.9% -2.6% 1Y 63.8% -8.5% 6.9%
See full shareholder returns
Return vs Market: MR4 exceeded the German Market which returned -11.9% over the past year.
Price Volatility Is MR4's price volatile compared to industry and market? MR4 volatility MR4 Average Weekly Movement 2.3% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: MR4 has not had significant price volatility in the past 3 months.
Volatility Over Time: MR4's weekly volatility (2%) has been stable over the past year.
About the Company Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT!
Show more Meridian Bioscience, Inc. Fundamentals Summary How do Meridian Bioscience's earnings and revenue compare to its market cap? MR4 fundamental statistics Market cap €1.38b Earnings (TTM ) €39.06m Revenue (TTM ) €306.34m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MR4 income statement (TTM ) Revenue US$333.02m Cost of Revenue US$144.66m Gross Profit US$188.36m Other Expenses US$145.90m Earnings US$42.46m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/02/01 07:48 End of Day Share Price 2023/01/30 00:00 Earnings 2022/09/30 Annual Earnings 2022/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Meridian Bioscience, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Catherine Ramsey Schulte Baird Mark Massaro Canaccord Genuity Zarak Khurshid Caris & Company
Show 12 more analysts 
